Examples: breast cancer, NCT03147287, pd-l1

Top 100 results for: "melanoma"

Enrolling

Pilot Trial of Olaparib in Patients with Unresectable or Metastatic Melanoma with Mutations in BRCA1/2 Genes

Trial Description: The purpose of this study is to evaluate how effective Olaparib is when given as a treatment for primary or recurrent, unresectable or metastatic melanoma. This research study involves targeted therapy. -The name of the study drug involved in this study is: Olaparib (also known as Lynparza)

  • Conditions: cutaneous melanoma, mucosal melanoma, recurrent metastatic melanoma, uveal melanoma
  • Phase: Feasibility / Pilot
  • Trial ID: NCT05482074
  • Protocol ID: 22-294

Not Enrolling

A Blinded, Randomized Phase 2 Study of Troriluzole in Combination with Ipilimumab and Nivolumab in Patientswith Melanoma Brain Metastases previously treated with anti-PD-1 therapy

Trial Description: The purpose of this research is to test the safety and effectiveness of the investigational combination of Troriluzole, ipilimumab, and nivolumab, and to learn whether this combination works in treating melanoma that has spread to the brain.

  • Conditions: melanoma, metastatic melanoma
  • Phase: II
  • Trial ID: NCT04899921
  • Protocol ID: 20-675

Enrolling

A Phase Ib study of NeoVax in combination with CDX-301 and nivolumab and in patients with melanoma

Trial Description: This research study is studying the drugs called NeoVax (a new type of personalized neoantigen vaccine) in combination with CDX-301 and Nivolumab as a possible treatment for melanoma. The names of the study drugs involved in this study are: - Personalized Neoantigen peptides (which combined with poly-ICLC make the vaccine NeoVax) - Poly-ICLC (Hiltonol) - CDX-301 - Nivolumab (Opdivo)

  • Conditions: melanoma, metastatic melanoma
  • Phase: I
  • Trial ID: NCT04930783
  • Protocol ID: 21-066

Enrolling

A Phase II trial of pembrolizumab (anti PD-1) therapy combined with sargramostim (GM-CSF) in Unresectable or Metastatic melanoma which has previously been treated with immune checkpoint inhibition

Trial Description: This research study is testing the combination of two drugs, sargramostim and pembrolizumab. The study is designed to see if the combination of these study drugs would improve the control of unresectable or metastatic melanoma cancer when compared to use of these drugs alone. The names of the study drugs involved in this study are: - Pembrolizumab - Sargramostim (GM-CSF)

  • Conditions: metastatic melanoma, stage iii melanoma, stage iv melanoma, unresectable melanoma
  • Phase: II
  • Trial ID: NCT04703426
  • Protocol ID: 20-370

Not Enrolling

"A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unresectable Melanoma"

Trial Description: The purpose of this study is to determine whether relatlimab in combination with nivolumab is more effective than nivolumab by itself in treating unresectable melanoma or melanoma that has spread.

  • Conditions: melanoma
  • Phase: II/III
  • Trial ID: NCT03470922
  • Protocol ID: 18-096

Not Enrolling

A PHASE II RANDOMIZED STUDY OF NIVOLUMAB (NSC-748726) WITH IPILIMUMAB (NSC-732442) OR IPILIMUMAB ALONE IN ADVANCED MELANOMA PATIENTS REFRACTORY TO AN ANTI-PD1 OR ANTI-PD-L1 AGENT

Trial Description: This phase II trial studies how well ipilimumab with or without nivolumab work in treating patients with melanoma that is stage IV or stage III and cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

  • Conditions: advanced melanoma, melanoma of unknown primary, mucosal melanoma, refractory melanoma, stage iii cutaneous melanoma ajcc v7, stage iiia cutaneous melanoma ajcc v7, stage iiib cutaneous melanoma ajcc v7, stage iiic cutaneous melanoma ajcc v7, stage iv cutaneous melanoma ajcc v6 and v7, unresectable cutaneous melanoma, unresectable melanoma
  • Phase: II
  • Trial ID: NCT03033576
  • Protocol ID: 19-714

Not Enrolling

A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma

Trial Description: The purpose of this study is to assess whether postoperative adjuvant therapy with mRNA-4157 and pembrolizumab improves recurrence free survival (RFS) compared to pembrolizumab alone in participants with complete resection of cutaneous melanoma and a high risk of recurrence.

  • Conditions: melanoma
  • Phase: II
  • Trial ID: NCT03897881
  • Protocol ID: 19-572

Not Enrolling

A MULTICENTER, TWO PART OPEN-LABEL, PHASE 1b CLINICAL STUDY OF CMP 001 ADMINISTERED EITHER IN COMBINATION WITH PEMBROLIZUMAB OR AS MONOTHERAPY IN SUBJECTS WITH ADVANCED MELANOMA

Trial Description: This study will be conducted in two parts: Part 1 will be conducted using a Dose Escalation and Expansion design. The Part 1 Dose Escalation Phase of this study will identify a safe and tolerable dose to be further evaluated in the Part 1 Dose Expansion phase. Part 2 of the study will be conducted in parallel with the Part 1 Dose Expansion Phase and will evaluate the safety and efficacy of CMP-001 when administered as a monotherapy. A Treatment Extension to assess the safety profile of CMP-001 when given in combination with pembrolizumab or as monotherapy will be available

  • Conditions: melanoma
  • Phase: I
  • Trial ID: NCT02680184
  • Protocol ID: 16-377

Not Enrolling

A randomized, open-label, multi-arm, two-part, phase II study to assess the efficacy and safety of multiple LXH254 combinations in patients with previously treated unresectable or metastatic BRAFV600 or NRAS mutant melanoma

Trial Description: The primary purpose of this study is to evaluate the efficacy of LXH254 combinations in previously treated unresectable or metastatic melanoma

  • Conditions: melanoma
  • Phase: II
  • Trial ID: NCT04417621
  • Protocol ID: 20-472

Not Enrolling

Adjuvant Therapy with Pembrolizumab versus Placebo in Resected Highrisk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE 716)

Trial Description: This 2-part study will evaluate the safety and efficacy of pembrolizumab (MK-3475) compared to placebo in participants with surgically resected high-risk Stage II melanoma. Participants in Part 1 will receive either pembrolizumab or placebo in a double-blind design every 3 weeks (Q3W) for up to 17 cycles/~1 year (each cycle = 21 days). Participants who complete the initial treatment of 17 cycles of pembrolizumab in Part 1 and experience disease recurrence may be eligible for re-challenge with pembrolizumab at the same dose and schedule of 200 mg Q3W (21-day cycles) for up

  • Conditions: melanoma
  • Phase: III
  • Trial ID: NCT03553836
  • Protocol ID: 18-434

Not Enrolling

A Phase 3, Randomized, Open-label Study of NKTR-214 Combined with Nivolumab Versus Nivolumab in Participants with Previously Untreated Unresectable or Metastatic Melanoma

Trial Description: The purpose of the study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug called NKTR-214, when combined with nivolumab versus nivolumab given alone in participants with previously untreated melanoma skin cancer that is either unable to be surgically removed or has spread

  • Conditions: melanoma
  • Phase: III
  • Trial ID: NCT03635983
  • Protocol ID: 18-489

Enrolling

A Phase Ib study of NeoVax plus Montanide in combination with Nivolumab and locally administered Ipilimumab in patients with melanoma

Trial Description: This research study is studying a new type of personalized neoantigen vaccine (NeoVax) plus Montanide® in combination with Ipilimumab (Yervoy™) and Nivolumab (Opdivo®) as a possible treatment for melanoma. The drugs involved in this study are: - Personalized Neoantigen Vaccine - Poly-ICLC (Hiltonol®) - Montanide® - Ipilimumab (Yervoy™) - Nivolumab (Opdivo®)

  • Conditions: melanoma
  • Phase: I
  • Trial ID: NCT03929029
  • Protocol ID: 18-279

Not Enrolling

A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy with Nivolumab versus Placebo after Complete Resection of Stage IIB/C Melanoma

Trial Description: The purpose of this study is to determine the effectiveness of nivolumab adjuvant immunotherapy compared to placebo in adults and pediatric participants after complete resection of Stage IIB/C melanoma with no evidence of disease (NED) who are at high risk for recurrence.

  • Conditions: melanoma
  • Phase: III
  • Trial ID: NCT04099251
  • Protocol ID: 19-494

Enrolling

A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination with Ipilimumab and Nivolumab in Patients with Unresectable Stage III or Stage IV Melanoma.

Trial Description: This is a Phase II, open-label, single arm study. The study will consist of an assessment of the safety and tolerability of tocilizumab administered concurrently at 4 mg/kg every 6 weeks for 5 doses in combination with ipilimumab and nivolumab for four induction doses to week 12, then maintenance nivolumab alone up to one year to patients with advanced melanoma. Treatment will be divided into induction and maintenance phases. It is anticipated that this clinical study will inform the use of this 3-drug combination for further phase II and/or phase III clinical testing. The trial will include an assessment of the pharmacodynamic activity of tocilizumab administered in combination with ipilimumab and nivolumab.

  • Conditions: melanoma
  • Phase: II
  • Trial ID: NCT03999749
  • Protocol ID: 19-852

Not Enrolling

A Phase I/II Study of MCS110 with BRAF/MEK Inhibition in Patients with Melanoma after Progression on BRAF/MEK Inhibition

Trial Description: This research study is studying a combination of targeted therapies as a possible treatment for advanced melanoma that was found to have a BRAF V600E or BRAF V600K genetic mutation. The interventions involved in this study are: - MCS110 - Dabrafenib - Trametinib

  • Conditions: melanoma
  • Phase: I/II
  • Trial ID: NCT03455764
  • Protocol ID: 17-656

Not Enrolling

A randomized, open-label, phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma

Trial Description: The primary purpose of this study is to evaluate the efficacy of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma

  • Conditions: melanoma
  • Phase: II
  • Trial ID: NCT03484923
  • Protocol ID: 18-625

Enrolling

A Phase Ib, Open-label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of IN10018 as Monotherapy and Combination Therapy in Subjects with Metastatic Melanoma

Trial Description: This is a phase Ib, open label clinical study to evaluate the safety, tolerability, PK and antitumor activities of IN10018 as monotherapy and in combination with cobimetinib in subjects with metastatic uveal melanoma and NRAS-mutant metastatic melanoma.

  • Conditions: metastatic melanoma
  • Phase: I
  • Trial ID: NCT04109456
  • Protocol ID: 19-889

Not Enrolling

A Phase II trial of neoadjuvant treatment with PD-1 inhibition (nivolumab) with or without IDO inhibition (BMS-986205) and with or without CTLA-4 inhibition (ipilimumab) in resectable stage III or IV melanoma

Trial Description: This research study is studying different immunotherapy regimens as a possible treatment for stage III or IV resectable melanoma.

  • Conditions: melanoma stage iii, melanoma stage iv
  • Phase: II
  • Trial ID: NCT04007588
  • Protocol ID: 19-043

Enrolling

A Phase 1, Open-Label, Dose-Escalation with Expansion Study of SX-682 in Subjects with Metastatic Melanoma Concurrently Treated with Pembrolizumab

Trial Description: Cancers attract myeloid-derived suppressor cells (MDSCs) that prevent our own immune responses from destroying the cancer. This study will be the first study to begin to determine if the newly discovered drug SX-682 can block cancers from attracting MDSCs. This first study will enroll participants with melanoma, as melanoma cancer has been shown to be able to attract MDSCs. The study will begin to determine if SX-682 is a safe and effective treatment of melanoma. It is thought that SX-682 will block MDSCs from going to the cancer, and thus will allow a patient's own immune

  • Conditions: melanoma stage iii, melanoma stage iv
  • Phase: I
  • Trial ID: NCT03161431
  • Protocol ID: 17-370

Enrolling

Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma (EA6141)

Trial Description: This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Colony-stimulating factors, such as sargramostim, may increase the production of white blood cells. It is not yet known whether nivolumab and ipilimumab are more effective with or without sargramostim in treating patients with melanoma.

  • Conditions: metastatic cutaneous melanoma, stage iii cutaneous melanoma ajcc v7, stage iv cutaneous melanoma ajcc v6 and v7, unresectable cutaneous melanoma
  • Phase: II/III
  • Trial ID: NCT02339571
  • Protocol ID: 15-724

Not Enrolling

A PHASE II, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF RO7198457 IN COMBINATION WITH PEMBROLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED MELANOMA

Trial Description: This study will evaluate the efficacy, safety, pharmacokinetics, and patient-reported outcomes (PROs) of RO7198457 plus pembrolizumab compared with pembrolizumab alone in patients with previously untreated advanced melanoma.

  • Conditions: advanced melanoma
  • Phase: II
  • Trial ID: NCT03815058
  • Protocol ID: 19-022

Not Enrolling

A phase II trial of abbreviated MAPK targeted therapy plus pembrolizumab in patients with unresectable or metastatic melanoma

Trial Description: This research study is studying a combination of drugs as a possible treatment for unresectable or metastatic melanoma. The drugs involved in this study are: - Pembrolizumab (Keytruda) - Trametinib (Mekinist) - Dabrafenib (Tafinlar)

  • Conditions: metastatic melanoma
  • Phase: II
  • Trial ID: NCT03149029
  • Protocol ID: 16-642

Not Enrolling

Multicenter Phase 1b Randomized, Placebo-controlled, Blinded Study to Evaluate the Safety, Tolerability and Efficacy of Microbiome Study Intervention Administration in Combination with Anti-PD-1 Therapy in Adult Patients with Unresectable or Metastatic Melanoma

Trial Description: This study is designed to evaluate the safety and tolerability of treatment with oral microbiome study intervention (SER-401) or matching placebo in combination with anti-programmed cell death 1 (anti-PD-1) therapy (nivolumab) in participants with unresectable or metastatic melanoma. The study also intends to assess clinical outcomes, the impact of microbiome study intervention administration on the microbiome profile, and its association with clinical and immunological outcomes.

  • Conditions: metastatic melanoma
  • Phase: I
  • Trial ID: NCT03817125
  • Protocol ID: 19-724

Not Enrolling

An Open-label, Phase 1B Study of NEO-PV-01 + CD40 Agonist Antibody (APX005M) or Ipilimumab with Nivolumab in Patients with Advanced or Metastatic Melanoma

Trial Description: The primary purpose of this study is to demonstrate that the NEO-PV-01 vaccine, either with APX005M or ipilimumab, and nivolumab is safe for the treatment of patients with advanced or metastatic melanoma. The study will also investigate an alternative schedule for the administration of the NEO-PV-01 vaccine. Study interventions will be assessed by both clinical and immune responses to treatment.

  • Conditions: metastatic melanoma
  • Phase: I
  • Trial ID: NCT03597282
  • Protocol ID: 18-624

Enrolling

Title: A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigator s Choice in HLA-A*0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma

Trial Description: To evaluate the overall survival of HLA-A*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investigator's Choice of dacarbazine, ipilimumab, or pembrolizumab

  • Conditions: uveal melanoma
  • Phase: II
  • Trial ID: NCT03070392
  • Protocol ID: 17-269

Not Enrolling

An Open-Label, Multicenter, Phase Ib Study To Evaluate Safety And Therapeutic Activity Of Ro6874281, An Immunocytokine, Consisting Of Interleukin-2 Variant (Il-2v) Targeting Fibroblast Activation Protein-Α (Fap), In Combination With Pembrolizumab (Anti-Pd-1), In Participants With Previously Untreate

Trial Description: This is an open-label, multicenter, Phase Ib study to evaluate the safety and therapeutic activity of RO6874281 in combination with pembrolizumab. The study will consist of 3 parts: a safety run-in (Part I: Cohorts 1.1. and 1.2) and two expansion parts (Parts II and III). Part II will start once all participants in Cohort 1.1 have completed the observation period. Part III will start once all participants in Cohorts 1.1 and 1.2 have completed the observation period

  • Conditions: metastatic melanoma
  • Phase: I
  • Trial ID: NCT03875079
  • Protocol ID: 19-175

Enrolling

A Phase II Trial of PD-L1 therapy combined with anti-VEGF therapy in Unresectable or Metastatic Melanoma

Trial Description: This research study is studying a combination of two drugs that change the immune system and tumor as a possible treatment for metastatic or unresectable stage III or IV cutaneous melanoma. The names of the study drugs involved in this study are: - Atezolizumab - Bevacizumab

  • Conditions: clinical stage iii cutaneous melanoma ajcc v8, stage iv melanoma, unresectable stage iii cutaneous melanoma, unresectable stage iv cutaneous melanoma
  • Phase: II
  • Trial ID: NCT04356729
  • Protocol ID: 19-604

Enrolling

A Phase I/II, multi-center, open label study of DYP688 in patients with metastatic uveal melanoma (MUM) and other GNAQ/11 mutant melanomas

Trial Description: This is a FIH, phase I/II, open label, multi-center study of DYP688 as a single agent. The purpose of this study is to characterize the safety, tolerability, and anti-tumor activity of DYP688 as a single agent in patients with metastatic uveal melanoma (MUM) and other melanomas harboring GNAQ/11 mutations.

  • Conditions: metastatic uveal melanoma
  • Phase: I/II
  • Trial ID: NCT05415072
  • Protocol ID: 22-326

Not Enrolling

"Phase I/II study of dabrafenib, trametinib, and navitoclax in BRAF mutant melanoma (Phase I and II) and other solid tumors (Phase I only)"

Trial Description: This phase I/II trial studies the side effects and best dose of dabrafenib, trametinib, and navitoclax and to see how well they work in treating patients with BRAF mutant melanoma or solid tumors that have spread to other parts of the body (metastatic) or cannot be removed by surgery (unresectable). Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Navitoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving navitoclax, dabrafenib, and trametinib may help shrink tumors in patients with melanoma.

  • Conditions: clinical stage iii cutaneous melanoma ajcc v8, clinical stage iv cutaneous melanoma ajcc v8, malignant solid neoplasm, metastatic melanoma, unresectable melanoma
  • Phase: I/II
  • Trial ID: NCT01989585
  • Protocol ID: 18-716

Not Enrolling

A Phase 2, Open-label, Multicenter Study Evaluating the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes (TILs) in Subjects with Advanced Melanoma

Trial Description: DELTA-1 is a phase 2 clinical trial to evaluate the efficacy and safety of ITIL-168 in adult subjects with advanced melanoma who have previously been treated with a PD-1 inhibitor. ITIL-168 is a cell therapy derived from a patient's own tumor-infiltrating immune cells (lymphocytes; TILs).

  • Conditions: advanced cutaneous melanoma
  • Phase: II
  • Trial ID: NCT05050006
  • Protocol ID: 20-698

Enrolling

A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered FHD-286 in Subjects with Metastatic Uveal Melanoma

Trial Description: This Phase 1, multicenter, open-label, dose escalation and expansion study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of FHD-286 oral monotherapy in subjects with metastatic Uveal Melanoma (UM).

  • Conditions: metastatic uveal melanoma
  • Phase: I
  • Trial ID: NCT04879017
  • Protocol ID: 21-029

Enrolling

Phase II Study of Infliximab for the Treatment of Ipilimumab Colitis

Trial Description: This research study is evaluating the effectiveness and safety of infliximab therapy compared with steroids in the treatment of ipilimumab-induced colitis in patients with III/IV melanoma.

  • Conditions: colitis, melanoma stage iii, melanoma stage iv, side effect of drug
  • Phase: II
  • Trial ID: NCT04305145
  • Protocol ID: 19-763

Enrolling

A Phase 1/1b, Open-Label Study of the Pressure-Enabled Hepatic Artery Infusion of SD-101, a TLR9 Agonist, Alone or in Combination with Intravenous Checkpoint Blockade in Adults with Metastatic Uveal Melanoma

Trial Description: This study is an open-label, phase 1/1b study of the pressure-enabled hepatic artery infusion of SD-101, a TLR 9 agonist, alone or in combination with intravenous checkpoint blockade in adults with metastatic uveal melanoma.

  • Conditions: metastatic uveal melanoma in the liver
  • Phase: I
  • Trial ID: NCT04935229
  • Protocol ID: 21-285

Not Enrolling

The PISCES Study: A Multicenter Phase 2, Open-Label Study of Intratumoral Tavokinogene Telseplasmid (tavo, pIL-12) plus Electroporation in Combination with Intravenous Pembrolizumab in Patients with Stage III/IV Melanoma who are Progressing on either Pembrolizumab or Nivolumab Treatment

Trial Description: Keynote 695 will be a Phase 2 study of intratumoral tavokinogene telseplasmid (tavo; pIL-12) Electroporation (EP) plus IV Pembrolizumab. Eligible patients will be those with pathological diagnosis of unresectable or metastatic melanoma who are progressing or have progressed on pembrolizumab or nivolumab.

  • Conditions: stage iii/iv melanoma
  • Phase: II
  • Trial ID: NCT03132675
  • Protocol ID: 19-206

Not Enrolling

A Phase I/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors

Trial Description: The purpose of the study is to assess the safety, tolerability and effectiveness of experimental medication BMS-986016 administered alone and in combination with nivolumab in patients with solid tumors that have spread and/or cannot be removed by surgery. The following tumor types are included in this study: Non-Small Cell Lung Cancer (NSCLC), gastric cancer, hepatocellular carcinoma, renal cell carcinoma, bladder cancer, squamous cell carcinoma of the head and neck, and melanoma, that have NOT previously been treated with immunotherapy. NSCLC and melanoma that HAVE previously been treated with immunotherapy.

  • Conditions: neoplasms by site
  • Phase: I/II
  • Trial ID: NCT01968109
  • Protocol ID: 13-410

Not Enrolling

A Phase 2, Open-Label, Multi-cohort Study of PD-L1 Probody™ Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors (PROCLAIM-CX-072)

Trial Description: To obtain evidence of antitumor effect of CX-072 in combination with anticancer therapy in adult patients with solid tumor based upon overall response rate by Response Evaluation Criteria in Solid Tumors (RECIST

  • Conditions: solid tumor, unresectable or metastatic melanoma
  • Phase: II
  • Trial ID: NCT03993379
  • Protocol ID: 19-482

Not Enrolling

Phase Ib study to test the safety and potential synergy of pembrolizumab (anti-PD-1) and AMG386 (angiopoietin-2 (Ang-2) in patients with advanced solid tumor

Trial Description: This research study is studying an investigational combination of drugs as a possible treatment for advanced solid tumors: melanoma, ovarian, renal, or colorectal cancer. The drugs involved in this study are: - Pembrolizumab - AMG386

  • Conditions: advanced solid tumor
  • Phase: I
  • Trial ID: NCT03239145
  • Protocol ID: 17-217

Not Enrolling

A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination with Nivolumab in Patients with Advanced/Metastatic Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer

Trial Description: This study is an open-label Phase 1/ 2 evaluation of CB-839 in combination with nivolumab in patients with clear cell renal cell carcinoma, melanoma, and non-small cell lung cancer.

  • Conditions: clear cell renal cell carcinoma (ccrcc), melanoma, non-small cell lung cancer (nsclc)
  • Phase: I/II
  • Trial ID: NCT02771626
  • Protocol ID: 16-379

Not Enrolling

A PHASE 1/2 STUDY OF NIVOLUMAB (IND# 124729) IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RECURRENT OR REFRACTORY SOLID TUMORS AS A SINGLE AGENT AND IN COMBINATION WITH IPILIMUMAB

Trial Description: This phase I/II trial studies the side effects and best dose of nivolumab when given with or without ipilimumab to see how well they work in treating younger patients with solid tumors or sarcomas that have come back (recurrent) or do not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether nivolumab works better alone or with ipilimumab in treating patients

  • Conditions: metastatic melanoma, recurrent ewing sarcoma/peripheral primitive neuroectodermal tumor, recurrent hodgkin lymphoma, recurrent malignant solid neoplasm, recurrent melanoma, recurrent neuroblastoma, recurrent non-hodgkin lymphoma, recurrent osteosarcoma, recurrent rhabdomyosarcoma, refractory ewing sarcoma/peripheral primitive neuroectodermal tumor, refractory hodgkin lymphoma, refractory malignant solid neoplasm, refractory melanoma, refractory neuroblastoma, refractory non-hodgkin lymphoma, refractory osteosarcoma, refractory rhabdomyosarcoma, stage iii cutaneous melanoma ajcc v7, stage iiia cutaneous melanoma ajcc v7, stage iiib cutaneous melanoma ajcc v7, stage iiic cutaneous melanoma ajcc v7, stage iv cutaneous melanoma ajcc v6 and v7, unresectable melanoma
  • Phase: I/II
  • Trial ID: NCT02304458
  • Protocol ID: 16-722

Not Enrolling

A Phase lb, open-label, multicenter study of oral LXH254 in combination with oral L TT462 in adult patients with advanced or metastatic KRAS or BRAF mutant Non-Small Cell Lung Cancer

Trial Description: To characterize safety and tolerability and identify a recommended dose and regimen for the LXH254 in combination with LTT462 or trametinib or ribociclib

  • Conditions: melanoma, non-small cell lung cancer
  • Phase: I
  • Trial ID: NCT02974725
  • Protocol ID: 17-117

Not Enrolling

A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY OF THE COMBINATION OF NKTR-214 AND NIVOLUMAB OR THE COMBINATION OF NKTR-214, NIVOLUMAB, AND OTHER ANTI-CANCER THERAPIES IN PATIENTS WITH SELECT LOCALLY ADVANCED OR METASTATIC SOLID TUMOR MALIGNANCIES

Trial Description: In this four-part study, NKTR-214 will be administered in combination with nivolumab in Part 1, in combination with nivolumab with or without various chemotherapies in Part 2, and with nivolumab in Parts 3 & 4. In Part 1, the Recommended Phase 2 Dose (RP2D) of NKTR-214 in combination with nivolumab will be determined. In Part 2, NKTR-214 with nivolumab at the RP2D will be evaluated as first-line therapy and/or as second or third line therapy in select patients with Melanoma, Renal Cell Carcinoma (RCC), Non-Small Cell Lung Cancer (NSCLC), Urothelial Carcinoma (UC), triple

  • Conditions: gastric cancer, hr+/her2- breast cancer, melanoma, non small cell lung cancer, renal cell carcinoma, triple negative breast cancer, urothelial carcinoma
  • Phase: I/II
  • Trial ID: NCT02983045
  • Protocol ID: 17-310

Enrolling

INSPIRE-AYA: A Multicenter INteractive Survivorship Program to Improve Healthcare REsources for Adolescent and Young Adult (AYA) Cancer Survivors

Trial Description: This trial studies how well an interactive survivorship program works in improving healthcare resources in adolescent and young adult cancer survivors. By improving access to survivorship resources, health literacy, self-management skills, and support, an interactive survivorship program may help to improve adherence to adolescent and young adult healthcare guidelines and reduce cancer-related distress

  • Conditions: clinical stage i cutaneous melanoma ajcc v8, clinical stage ia cutaneous melanoma ajcc v8, clinical stage ib cutaneous melanoma ajcc v8, clinical stage ii cutaneous melanoma ajcc v8, clinical stage iia cutaneous melanoma ajcc v8, clinical stage iib cutaneous melanoma ajcc v8, clinical stage iic cutaneous melanoma ajcc v8, clinical stage iii cutaneous melanoma ajcc v8, hematopoietic and lymphoid cell neoplasm, invasive malignant neoplasm, leukemia, lymphoma, malignant solid neoplasm, pathologic stage i cutaneous melanoma ajcc v8, pathologic stage ia cutaneous melanoma ajcc v8, pathologic stage ib cutaneous melanoma ajcc v8, pathologic stage ii cutaneous melanoma ajcc v8, pathologic stage iia cutaneous melanoma ajcc v8, pathologic stage iib cutaneous melanoma ajcc v8, pathologic stage iic cutaneous melanoma ajcc v8, pathologic stage iii cutaneous melanoma ajcc v8, pathologic stage iiia cutaneous melanoma ajcc v8, pathologic stage iiib cutaneous melanoma ajcc v8, pathologic stage iiic cutaneous melanoma ajcc v8, sarcoma, stage i colorectal cancer ajcc v8, stage ii colorectal cancer ajcc v8, stage iia colorectal cancer ajcc v8, stage iib colorectal cancer ajcc v8, stage iic colorectal cancer ajcc v8, stage iii colorectal cancer ajcc v8, stage iiia colorectal cancer ajcc v8, stage iiib colorectal cancer ajcc v8, stage iiic colorectal cancer ajcc v8
  • Phase: Not Applicable
  • Trial ID: NCT04593277
  • Protocol ID: 20-758

Not Enrolling

A phase I dose finding study of oral LXH254 in adult patients with advanced solid tumors harboring MAPK pathway alterations

Trial Description: A Phase I Study of LXH254 in Patients With Advanced Solid Tumors That Harbor MAPK Pathway Alterations

  • Conditions: melanoma, nsclc, other solid tumors, ovarian cancer
  • Phase: I
  • Trial ID: NCT02607813
  • Protocol ID: 18-108

Enrolling

A Phase 1 Trial of Intralesional Immunotherapy with IFx-Hu2.0 Vaccine in Patients with Advanced Non Melanoma

Trial Description: In this clinical phase I, non-randomized, open-label, uncontrolled, interventional, multi-center trial, 20 adult subjects (≥ 18 years of age) with advanced non-melanoma skin cancers will receive a fixed dose of 0.1 mg of IFx-Hu2.0 intralesionally as monotherapy in up to three lesions at up to three time points. Subjects will be observed for any acute adverse events (AEs) post injection and for any delayed AEs at Day 28, 35 and/or 42 ± 7 days, depending on the cohort (exposure escalation and expansion design).

  • Conditions: cutaneous squamous cell carcinoma, merkel cell carcinoma, non-melanoma skin cancers
  • Phase: I
  • Trial ID: NCT04160065
  • Protocol ID: 19-871

Not Enrolling

A phase 1b/2a, open label study to evaluate anti-tumor efficacy and safety of rhIL-7-hyFc (NT-I7) in combination with anti-PD-L1 (atezolizumab) in patients with anti-PD-1/PD-L1 naïve or relapsed/refractory high-risk skin cancers

Trial Description: The purpose of this study is to test whether the addition of NT-I7 to atezolizumab provides clinically meaningful outcomes for patients with anti-PD-1/PD-L1 naive or relapsed/refractory high-risk melanoma, Merkel Cell Carcinoma (MCC) and cutaneous Squamous Cell Carcinoma (cSCC)

  • Conditions: cutaneous squamous cell carcinoma, melanoma, merkel cell carcinoma
  • Phase: I/II
  • Trial ID: NCT03901573
  • Protocol ID: 19-446

Enrolling

A Phase II Study of Talimogene laherparepvec Followed by Talimogene laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors

Trial Description: This phase II trial studies how well talimogene laherparepvec and nivolumab work in treating patients with lymphomas that do not responded to treatment (refractory) or non-melanoma skin cancers that have spread to other places in the body (advanced) or do not responded to treatment. Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop tumor cells from growing. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving talimogene laherparepvec and nivolumab may work better compared to usual treatments in treating patients with lymphomas or non-melanoma skin cancers.

  • Conditions: adenoid cystic skin carcinoma, adnexal carcinoma, anaplastic large cell lymphoma alk-negative, anaplastic large cell lymphoma alk-positive, apocrine carcinoma, cylindrocarcinoma, digital papillary adenocarcinoma, endocrine mucin-producing sweat gland carcinoma, extramammary paget disease, extraocular cutaneous sebaceous carcinoma, hidradenocarcinoma, keratoacanthoma, malignant sweat gland neoplasm, merkel cell carcinoma, microcystic adnexal carcinoma, nk-cell lymphoma unclassifiable, papillary adenocarcinoma, porocarcinoma, primary cutaneous mucinous carcinoma, recurrent mature t-cell and nk-cell non-hodgkin lymphoma, recurrent t-cell non-hodgkin lymphoma, refractory anaplastic large cell lymphoma, refractory mature t-cell and nk-cell non-hodgkin lymphoma, refractory merkel cell carcinoma, refractory mycosis fungoides, refractory primary cutaneous t-cell non-hodgkin lymphoma, refractory skin squamous cell carcinoma, refractory t-cell non-hodgkin lymphoma, sezary syndrome, signet ring cell carcinoma, skin basal cell carcinoma, skin basosquamous cell carcinoma, skin squamous cell carcinoma, spiradenocarcinoma, squamoid eccrine ductal carcinoma, squamous cell carcinoma of unknown primary, sweat gland carcinoma, trichilemmal carcinoma, vulvar squamous cell carcinoma
  • Phase: II
  • Trial ID: NCT02978625
  • Protocol ID: 17-753

Enrolling

A Phase I/II Study of MK-3475 (Pembrolizumab) in Children with advanced melanoma or a PD-L1 positive advanced, relapsed or refractory solid tumor or lymphoma

Trial Description: This is a two-part study of pembrolizumab (MK-3475) in pediatric participants who have any of the following types of cancer: - advanced melanoma (6 months to <18 years of age), - advanced, relapsed or refractory programmed death-ligand 1 (PD-L1)-positive malignant solid tumor or other lymphoma (6 months to <18 years of age), - relapsed or refractory classical Hodgkin lymphoma (rrcHL) (3 years to <18 years of age), or - advanced relapsed or refractory microsatellite-instability-high (MSI-H) solid tumors (6 months to <18 years of age), or - advanced relapsed or refractory

  • Conditions: classical hodgkin lymphoma, lymphoma, melanoma, microsatellite-instability-high solid tumor, solid tumor
  • Phase: II
  • Trial ID: NCT02332668
  • Protocol ID: 16-235

Not Enrolling

A Phase 1b/2, Open-label, Dose Escalation Study of Entinostat in Combination with Pembrolizumab in Patients with Non-small Cell Lung Cancer, with Expansion Cohorts in Patients with Non-small Cell Lung Cancer, Melanoma and Mismatch Repair-Proficient Colorectal Cancer

Trial Description: The purpose of this study is to determine the safety and tolerability of entinostat used in combination with pembrolizumab in patients with Non-small Cell Lung Cancer. Additionally, the purpose of the study is to assess how effective entinostat and pembrolizumab are in combination in patients with Non-small Cell Lung Cancer, Melanoma, and Mismatch-Repair Proficient Colorectal Cancer

  • Conditions: melanoma, mismatch repair-proficient colorectal cancer, non-small cell lung cancer
  • Phase: I/II
  • Trial ID: NCT02437136
  • Protocol ID: 15-322

Not Enrolling

A Phase I/2a, Open-Label, Dose Escalation and Expansion study of the Safety and Tolerability of T3011 when Administered via Intertumoral Injection as a Single agent in Combination with Intravenous Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors

Trial Description: This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced or metastatic solid tumors

  • Conditions: hnscc, melanoma, nsclc, sarcoma, solid tumor, squamous cell carcinoma
  • Phase: I/II
  • Trial ID: NCT04370587
  • Protocol ID: 20-351